A-shares across the board today**, the Shanghai Composite Index performed relatively firmly. Specifically, the Shanghai Composite Index fell intraday, the Shenzhen Component Index and the ChiNext Index plunged sharply, the ChiNext Index and the Kechuang 50 Index both fell more than 2% in the afternoon, and the Beijing Stock Exchange 50 Index fell more than 3%. As of **, the Shanghai Composite Index fell 041% at 30274 points, the Shenzhen Component Index fell 137% at 9267At 12 points, the GEM index fell 233% at 178994 points, the Science and Technology Innovation 50 Index fell 218%, the Beijing Stock Exchange 50 Index fell 361%；The total turnover of the two cities was 981.7 billion yuan, an increase of 50 billion yuan from yesterday.
In other news, the central bank released data showing that China's ** reserves increased for the 16th consecutive month, with ** reserves of 72.58 million ounces at the end of February, an increase of 390,000 ounces from the previous month, and 72.19 million ounces at the end of January.
The central bank's ** reserves have increased for 16 consecutive years! * The concept performance is outstanding
According to data released by the State Administration of Foreign Exchange on March 7, as of the end of February 2024, China's foreign exchange reserves were US$3,225.8 billion, an increase of US$6.5 billion or 020%。
The State Administration of Foreign Exchange said that in February, affected by macroeconomic data of major economies, monetary policy expectations and other factors, the US dollar index and global financial assets were mixed. Factors such as exchange rate translation and changes in assets** combined to increase the scale of foreign exchange reserves in the month. China's economy is resilient, has great potential and is full of vitality, and the long-term positive trend of the economy will continue to consolidate and strengthen, which is conducive to maintaining the basic stability of the scale of foreign exchange reserves.
On the same day, the central bank released data showing that China's ** reserves increased for the 16th consecutive month, with ** reserves of 72.58 million ounces at the end of February, an increase of 390,000 ounces from the previous month, and 72.19 million ounces at the end of January.
Recently, the international and domestic *** has continued to rise. London spot**, comex*** recently refreshed the historical record, today, London spot** intraday hit a record high, to 2161At $53 an ounce, COMEX*** hit an intraday high of $2,169 an ounce, setting a new all-time record. In terms of domestic gold prices, as of **, SHFE**50588 yuan grams, a new record high. On March 7, according to the main domestic brand gold stores, Chow Sang Sang, Chow Tai Fook, Luk Fook Jewelry, etc., all exceeded 650 grams, and Caibai jewelry ** was the lowest 626 yuan grams.
Affected by this, in the context of today's overall adjustment, the concept of ** performance is outstanding. As of **, Sichuan** daily limit, Western ** (601069) rose more than 9%, Tongling Nonferrous Metals (000630) rose more than 7%, Western Mining (601168), Yulong shares (601028) rose more than 5%.
According to data released by the China ** Association a few days ago, in 2023, the national ** consumption will be 108969 tons, a year-on-year increase of 878%。Among them, the consumption of ** jewelry is 70648 tons, a year-on-year increase of 797%；The consumption of gold bars and coins was 29960 tons, a year-on-year increase of 157%。The China ** Association said that driven by a series of policies to boost consumption, the national consumer market continued to recover and rebound, and gold, silver and jewelry became the fastest growing category among all commodity retail categories in 2023.
Dongxing** pointed out that looking forward to 2024, a variety of factors may continue to support the high operation of gold prices: (1) major Western economies represented by the Federal Reserve have entered the channel of interest rate cuts; (2) the geopolitical crisis is still tense and will not disappear anytime soon; (3) The demand of global central banks for ** is still increasing, and the increase in ** reserves will continue. Against this backdrop, ** is expected to continue to gain traction among investors and consumers as a safe-haven asset. At the same time, the enthusiasm of major domestic first-class jewelry companies to open stores is high, and the confidence of franchisees to open stores after the epidemic has increased significantly, and the brand side has also given greater support, and the industry is expected to maintain good sales performance.
The rise of the tourism sector
The tourism and travel sector rose rapidly intraday, as of **, Dalian Shengya (600593), Changbai Mountain (603099) rose by the limit, Tianmu Lake (603136) rose nearly 8%, Jiuhua Tourism (603199), Zhangjiajie (000430) rose by more than 5%.
On the news side, the Consular Department of ** issued a document today saying that in order to further promote personnel exchanges between China and foreign countries, China has decided to expand the scope of visa-free countries and try out the visa-free policy for ordinary passport holders from six countries: Switzerland, Ireland, Hungary, Austria, Belgium and Luxembourg. From March 14 to November 30, 2024, holders of ordinary passports from the above-mentioned countries can enter China visa-free for business, sightseeing, visiting relatives and friends and transiting through the border for no more than 15 days.
After the news was announced, the search volume of inbound and outbound air tickets of relevant countries on the travel platform was rapid**, and this morning, the search volume of air tickets related to some platforms increased by nearly 4 times compared with the same period the day before.
The agency said that the recovery of inbound and outbound tourism will speed up again, and the number of visa-free countries and entry and exit policies are still expected to continue to be optimized in the future, and it is recommended to pay attention to listed companies related to the tourism industry chain that are expected to benefit from the continuous recovery of inbound and outbound tourism.
The CXO concept took a big dive
As of **, Pharmaron (300759) fell more than 10%, and Gloria (002821) and Tigermed (300347) fell about 7%.
It is worth noting that WuXi AppTec (603259), which has a market value of more than 150 billion, fell to 5286 yuan, the full-day transaction is 60400 million yuan. It is worth noting that this is the fourth time that the stock has fallen this year.
WuXi Biologics and WuXi AppTec both fell by more than 20% and WuXi XDC fell by nearly 10%.
It is understood that the "WuXi Department" fell collectively again, or it may still be disturbed by the news related to the US "Biosafety Act".
According to a ** report, at about 10 o'clock in the evening of the 6th, Beijing time, the U.S. Senate Homeland Security Committee held a hearing on the proposal, and the U.S. Senate version of the "Biosecurity Act" (S3558) was passed by an 11-1 vote at the meeting, and the next step is that the committee is expected to carry out internal work on the revision of the bill before revising the Biosafety Act (S3558) was sent to the Senate for a vote by all members, but the date for the Senate deliberation has not yet been announced.
At noon today, WuXi AppTec quickly issued an announcement saying that the company learned that the U.S. Senate Homeland Security and ** Affairs Committee voted to report to the Senate a revised draft bill on March 6, 20243558 (hereinafter referred to as the "Draft"). The amendments to the Bill include, but are not limited to, a non-retroactive clause exempting existing contracts entered into prior to the entry into force of the proposed legislation; and procedures for designating and reviewing "companies of concern" by U.S.** agencies. Despite these revisions and the existing issue assessment procedures of U.S.** institutions, the draft pre-defines WuXi AppTec as one of the "biotechnology companies of concern". The Company strongly opposes this prior and unfair definition without due process, and the Company firmly believes that WuXi AppTec has not, is, and will not pose a *** risk to the United States or any other country in the past. The Company also reiterates that WuXi AppTec does not have a human genomics business and does not collect human genome data from its existing businesses.
In the coming months, the draft will continue to go through the legislative process in the Senate. The Company will continue to engage in communication and dialogue with stakeholders involved in the draft and the ongoing legislative process for corresponding U.S. House of Representatives bills, which are subject to further consideration and subject to change.
In addition, Pharmaron's Hong Kong stock fell about 16%, and the company said on the investor interactive platform that the company is committed to providing new drug development and manufacturing services that comply with the highest international standards for global innovative drug R&D companies, and the relevant laws are not expected to affect the company's development. At present, the company's operation and business development at home and abroad are normal and orderly, and we will continue to pay attention to changes in external policies.
Multiple ** dives
A number of strong stocks plunged sharply today, Kelai Electromechanical (603960) and Anel (002875) both fell to the limit, and Furong Technology (603327) approached the fall limit.
Specifically, Kelai Electromechanical plunged sharply in the intraday, and as of **, the stock reported 3828 yuan, about 550,000 lots. It is worth noting that the stock has risen by 258% in 19 trading days from February 1 to March 6, of which 14 trading days have a daily limit.
The company issued a risk warning yesterday evening, saying that it has recently paid attention to rumors that the company will be listed as a new quality productivity concept stock. The concept of new qualitative productivity is broad and covers a wide range of areas. The company's existing main business is still intelligent equipment and auto parts, which belongs to the traditional manufacturing field, the company's related products have not changed, the company's R&D investment in 2023 accounts for the proportion of the company's operating income is basically the same as that in 2022, and there is no significant difference with comparable listed companies in the same industry.
At present, the company's production and operation activities are normal, and the internal production and operation order is normal. The company's business has remained stable in recent years, and there have been no major changes in the business segments, and there have been no major changes in the company's major customers and fundamentals. The company's intelligent equipment business is affected by the cyclical fluctuations of fixed asset investment in downstream industries, resulting in the risk of fluctuations in the company's operating performance. The company's 2023 intelligent equipment business signed a new order 22.2 billion yuan, a decrease from the same period last year, the company's performance growth in 2023 is mainly based on the original auto parts business, and the performance growth basis has not changed significantly.
Recently, Anel of the 7th board also dived and fell to the limit, as of **, the stock reported 1913 yuan, the limit of the board on the seal of more than 330,000 lots. The company also reminded yesterday evening that the company's stock price has fluctuated greatly recently, and the valuation is significantly higher than that of listed companies in the same industry. On December 15, 2023, the company disclosed the "Announcement on the Proposed Acquisition of 22% Equity of Shenzhen Innovation Technology ***". Since the other shareholders of the target company, Innovation Branch, have the right of first refusal, whether the shareholders of Innovation Technology exercise the right of first refusal is a prerequisite for this transaction. As of the disclosure date of the announcement, the company has not received a written notice from the counterparty Zhuoyun Zhichuang on whether other shareholders of Innovation Technology have exercised their preemptive rights, so there is still uncertainty in this transaction.
Recently, Furong Technology, which has 5 boards, is approaching the fall limit, and the company clarified yesterday evening that the company's main business is the research and development, production and sales of aluminum structural materials for consumer electronics. The company's main products are aluminum structural materials for consumer electronics, which are further processed for smartphones, tablets and laptops. The company's products do not have AI capabilities.
In addition, Rongke Technology (300290), which has risen by more than 120% in the past 10 trading days, fell by more than 10%. The company reminded yesterday evening that the company's fundamentals have not changed, the company's stock price is sharply **, and there are irrational factors. The company's price-earnings ratio deviates from the company's fundamentals and the reasonable valuation of listed companies in the same industry. The company reminds investors to pay attention to the risks of secondary market transactions, make rational decisions and invest prudently.